Neurocrine Biosciences, Inc. (NBIX)
| Previous close | 104.59 |
| Open | 104.50 |
| Bid | 107.77 x 800 |
| Ask | 107.99 x 800 |
| Day's range | 103.09 - 108.60 |
| 52-week range | 71.88 - 108.60 |
| Volume | |
| Avg. volume | 749,385 |
| Market cap | 10.375B |
| Beta (5Y monthly) | 0.58 |
| PE ratio (TTM) | 148.60 |
| EPS (TTM) | 0.73 |
| Earnings date | 31 Oct 2022 - 04 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 29 Dec 1995 |
| 1y target est | 113.52 |
- Motley Fool
Neurocrine Biosciences (NBIX) Q2 2022 Earnings Call Transcript
With me are Kevin Gorman, our chief executive officer; Matthew Abernethy, our chief financial officer; Eiry Roberts, our chief medical officer; Eric Benevich, our chief commercial officer; and Kyle Gano, our chief business development and strategy officer. During a call, we will be making forward-looking statements.
- Globe Newswire
Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine Biosciences
Neurocrine to conduct placebo-controlled Phase 2 study to investigate NBI-1117568 (formerly HTL-0016878) as a potential new treatment for schizophrenia Clinical development milestone triggers payment of US$30 million to Sosei Heptares from NeurocrineNBI-1117568 is the most advanced candidate under the multi-program muscarinic receptor agonist collaboration between Sosei Heptares and Neurocrine TOKYO and CAMBRIDGE, United Kingdom, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Co
- Zacks
Neurocrine Biosciences (NBIX) Reports Q2 Loss, Tops Revenue Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of -132.14% and 11.03%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
